Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Functional microRNA-targeting drug discovery by graph-based deep learning. | Patterns (N Y) | 2024 | 38264717 | PubTator, text mining | PubMed |
| Comprehensive and accurate genome analysis at scale using DRAGEN accelerated algorithms. | bioRxiv | 2024 | 38260545 | PubTator, text mining | PubMed |
| Splicing Modulation via Antisense Oligonucleotides in Recessive Dystrophic Epidermolysis Bullosa. | Int J Mol Sci | 2024 | 38255836 | PubTator, text mining | PubMed |
| Beyond C9orf72: repeat expansions and copy number variations as risk factors of amyotrophic lateral sclerosis across various populations. | BMC Med Genomics | 2024 | 38254109 | PubTator, text mining | PubMed |
| Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry. | J Neuromuscul Dis | 2024 | 38250783 | PubTator, text mining | PubMed |
| Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care. | BioTech (Basel) | 2024 | 38247731 | PubTator, text mining | PubMed |
| Onasemnogene Abeparvovec: Post-infusion Efficacy and Safety in Patients With Spinal Muscular Atrophy (SMA)-A Fondazione Policlinico Gemelli IRCCS Experience. | Hosp Pharm | 2024 | 38223869 | PubTator, text mining | PubMed |
| A super minigene with a short promoter and truncated introns recapitulates essential features of transcription and splicing regulation of the SMN1 and SMN2 genes. | Nucleic Acids Res | 2024 | 38214229 | PubTator, text mining | PubMed |
| Gene replacement therapy in spinal muscular atrophy: filling the data gaps. | Lancet Reg Health Eur | 2024 | 38205071 | PubTator, text mining | PubMed |
| Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain. | J Neuromuscul Dis | 2024 | 38189761 | PubTator, text mining | PubMed |
| 270th ENMC International Workshop: Consensus for SMN2 genetic analysis in SMA patients 10-12 March, 2023, Hoofddorp, the Netherlands. | Neuromuscul Disord | 2024 | 38183850 | PubTator, text mining | PubMed |
| Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. | Commun Med (Lond) | 2024 | 38182878 | PubTator, text mining | PubMed |
| QR-1011 restores defective ABCA4 splicing caused by multiple severe ABCA4 variants underlying Stargardt disease. | Sci Rep | 2024 | 38182646 | PubTator, text mining | PubMed |
| Applications of CRISPR technologies to the development of gene and cell therapy. | BMB Rep | 2024 | 38178651 | PubTator, text mining | PubMed |
| [An evaluation of carrier detection for Spinal muscular atrophy using digital PCR assay]. | Zhonghua Yi Xue Yi Chuan Xue Za Zhi | 2024 | 38171554 | PubTator, text mining | PubMed |
| Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom. | Lancet Reg Health Eur | 2024 | 38169987 | PubTator, text mining | PubMed |
| Carrier frequency estimation of pathogenic variants of autosomal recessive and X-linked recessive mendelian disorders using exome sequencing data in 1,642 Thais. | BMC Med Genomics | 2024 | 38167091 | PubTator, text mining | PubMed |
| Parental Experiences with Newborn Screening and Gene Replacement Therapy for Spinal Muscular Atrophy. | J Neuromuscul Dis | 2024 | 38160362 | PubTator, text mining | PubMed |
| A high-fidelity long-read sequencing-based approach enables accurate and effective genetic diagnosis of spinal muscular atrophy. | Clin Chim Acta | 2024 | 38158006 | PubTator, text mining | PubMed |
| Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio. | Neuromuscul Disord | 2024 | 38142474 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=18